Additional Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Cedars Sinai Medical Center
    Los Angeles CA. 90048
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Cleveland Clinic Florida
    Weston FL. 33331
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    University of North Carolina at Chapel Hill
    Chapel Hill NC. 27514
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    National Jewish Health
    Denver CO. 80206
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Yale University School of Medicine
    New Haven CT. 06511
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    University of Kansas Medical Center
    Kansas City MO. 66160
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Henry Ford Health
    Detroit MI. 48202
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Medical University of South Carolina
    Charleston SC. 29425
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    Paradigm Clinical Research Centers, LLC
    San Diego CA. 92108
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    UAB Lung Health Center
    Birmingham AL. 35233
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    The Lung Research Center, LLC
    Chesterfield MO. 63017
    View Details

  • A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

    El Paso Pulmonary Association
    El Paso TX. 79902
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Utah
    Salt Lake City UT. 84108
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    The University of Kansas Medical Center
    Kansas City KS. 66160
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Johns Hopkins Asthma and Allergy Center
    Baltimore MD. 21205
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Research Institute McGill University Health Center
    Montreal QC. H4A 3J1
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Southern California
    Los Angeles CA. 90033
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Alabama at Birmingham
    Birmingham AL. 35205
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Maryland
    Baltimore MD. 21201
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Inova Healthcare
    Falls Church VA. 22042
    View Details